In the U.S. where adoption is highest, fewer than 1 in 10 adults are on a GLP-1 drug, despite nearly three-quarters being overweight or obese. Globally access is even more limited, held back by high ...

A trial of 3,127 patients who took a daily pill for 72 weeks saw an average weight loss per person of 12.3kg. While injectable obesity drugs are peptides designed to replicate the appetite-controlling ...